Clinical trials: Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4)…
- Trial name
- NCT01892345
- Testing
- Eculizumab
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 143 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica, Devic's Disease
Autologous Transplant To End NMO Spectrum Disorder
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term…
- Conditions
- Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
- Trial name
- ATTEND (NCT03829566)
- Testing
- Rituximab, Cyclophosphamide, Mesna
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Neuroimmune diseases are more prevalent among women of reproductive age. Studies have shown that neuroimmune diseases may impact fertility.
- Conditions
- Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis, Autoimmune Encephalitis, Myasthenia Gravis
- Trial name
- RANID (NCT07653984)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Neuromyelitis Optica Spectrum Disorders (NMOSD)
HANDLE-a Real World Study on Satralizumab in NMOSD
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting…
- Trial name
- NCT06829524
- Testing
- Satralizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Neuromyelitis Optica Spectrum Disorder Attack
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG).
- Trial name
- EASE-NMO (NCT06673394)
- Testing
- Complement protein C5 inhibitor, IVMP
- Sponsor
- Tianjin Medical University General Hospital
Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica Spectrum Related Disorders
The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
Devic's neuromyelitis optica (NMO) is rare. Epidemiological and demographic data are poor, based mainly on monocentric cohorts. Moreover, NMO might be difficult to distinguish from multiple sclerosis and begin with atypical or…
- Trial name
- NOMADMUS (NCT02850705)
- Where
- France
- Volunteers
- 1,787 people
- Sponsor
- Hospices Civils de Lyon
Neuromyelitis Optica Spectrum Disorder Attack
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage.
- Trial name
- ETA/PETA-NMOSD (NCT07410039)
- Testing
- Eculizumab+IVMP, IVIG+IVMP, IVMP
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Myasthenia Gravis Generalised, Vaccination
Meningococcal Vaccination in Patients on Complement Inhibitors
Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies directed predominantly against components of the postsynaptic membrane of the neuromuscular junction.
- Conditions
- Myasthenia Gravis Generalised, Vaccination, Complement System, Neuromyelitis Optica Spectrum Disease (NMOSD)
- Trial name
- Vax_MenACWY (NCT06906692)
- Testing
- Serum Bactericidal Assay
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NMO Spectrum Disorder
ACT with NMOSD Patients and Caregivers Pilot Study
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their…
- Trial name
- NCT05840055
- Testing
- Acceptance and Commitment Therapy
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Neuromyelitis Optica Spectrum Disorders
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients.
- Trial name
- NCT06697535
- Testing
- JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Neuromyelitis Optica
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
The aim of this study is to determine whether self-administered, at-home use of a transcutaneous electrical nerve stimulating device is an effective, acceptable and feasible method of relief from neuropathic pain among patients…
- Trial name
- NCT04614454
- Testing
- High Frequency Impulse Therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Neuromyelitis Optica Spectrum Disorder Relapse
Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse
To evaluate the safety and tolerability of allogeneic bone marrow-derived mesenchymal stem cells (CE211NS21) in patients with severe anti-aquaporin-4-immunoglobulin G positive neuromyelitis optica spectrum disorder…
- Trial name
- NCT07595965
- Testing
- CE211NS21
- Volunteers
- 6 people
- Sponsor
- Corestemchemon, Inc.
Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
This study is a multicenter, prospective, randomized, double-blind, placebo-controlled exploratory investigation conducted in China.
- Trial name
- TERMINATOR (NCT07699770)
- Testing
- Crisugabalin
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Tang-Du Hospital
Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation).
- Trial name
- PET-AON (NCT06453694)
- Testing
- Efgartigimod Alfa
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Anastasia Vishnevetsky, MD, MPH
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
This is an observational study to monitor female participants exposed to UPLIZNA during pregnancy. This study requires voluntary reporting of pregnancies in female participants with NMOSD exposed to UPLIZNA during pregnancy or…
- Trial name
- NCT05909761
- Testing
- UPLIZNA
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Amgen
Assessment of Serum FAM19A5level in Egyptian Patients With NMOSD
Assessment of Serum FAM19A5 Level in Egyptian Patients With Neuromyelitis Optica Spectrum Disorder
Neuromyelitis optica spectrum disorders (NMOSD) are severe inflammatory autoimmune conditions of the central nervous system (CNS) .
- Trial name
- NCT05446701
- Testing
- serum level of FAM19A5
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assiut University
NMOSD, Neuromyelitis Optica Spectrum Disorders
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).
- Trial name
- ECU-NMO-304 (NCT06724809)
- Testing
- eculizumab
- Where
- 7 sites in China
- Volunteers
- 21 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack
Diagnosis of ON With or Without MS or NMOSD
This is both a prospective and retrospective study of patients with a known diagnosis of optic neuritis (ON) only, multiple sclerosis (MS) with ON, or neuromyelitis spectrum disorder (NMOSD) with ON.
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression
- Trial name
- NCT04131764
- Testing
- Reflex (Brightlamp Inc., Purdue University)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Jagannadha R Avasarala
Neuromyelitis Optica Spectrum Disorders, MOGAD
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.
The goal of this study is to assess the frequency of genetic polymorphisms of the FCG3A in a cohort of Italian patients affected by neuromyelitis optica spectrum disorder (NMOSD) and mog antibody associated disease (MOGAD) and in…
- Conditions
- Neuromyelitis Optica Spectrum Disorders, MOGAD, Multiple Sclerosis
- Trial name
- PoGe (NCT06865274)
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NMO Spectrum Disorder
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.
- Trial name
- NCT05145361
- Testing
- B001 injection
- Where
- 4 sites in China
- Volunteers
- 45 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd